Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Patients with carcinoid tumours frequently present with metastatic disease. There are only a few therapeutic options for these patients, and the main goal of palliative treatment is to reduce symptoms and thus to improve quality of life. Current therapy includes surgical resection, hepatic artery embolisation, chemotherapy and somatostatin analogue treatment; however, all these options have limitations. It seems probable that therapeutic modalities based on radiopharmaceuticals may provide better therapy, not only in relation to symptom reduction but may also improve patient survival. In this case report we present a 46-year-old woman with a symptomatic carcinoid, who at the time of diagnosis had liver and abdominal lymph node metastases, the primary tumour being located in the terminal ileum. (111)In-pentetreotide scanning was negative, whereas (123)I-MIBG scanning showed high avidity in the tumour tissue. After right hemicolectomy, two courses of (131)I-MIBG treatment were given (12.95 GBq and 12 GBq, respectively). After the second dose of (131)I-MIBG temporary pancytopenia was present. Octreotide therapy was given empirically only for a short time and was stopped because of drug intolerance. The patient underwent tricuspid and pulmonary valve replacement because of her carcinoid heart disease, followed by two courses of embolisation of liver metastases. While (131)I-MIBG therapy reduced the patient's symptoms of flushing and diarrhoea, there has not yet been any effect on tumour response or 5-HIAA production. This case illustrates the multimodality and multidisciplinary approach to such patients.
Endokrynol Pol
PMID:Multimodality palliative treatment of (111)In-pentetreotide negative/(123)I-MIBG positive metastatic carcinoid - a case report. 1877 5

Genetic manipulation conducted for many years has resulted in breeding turkeys with very intensive growth rate and high percentage of muscle tissue. These features promote dysfunctions in the cardiovascular system. The aim of this article was to present current data on the etiology of cardiovascular system diseases in turkeys. In this paper the most recent data on dilated cardiomyopathy (round heart disease), spontaneous aortic rupture and perirenal hemorrhage syndrome are described.
Pol J Vet Sci 2008
PMID:Cardiovascular system diseases in turkeys. 1894 48

As a result of population ageing and improved medical care that contribute to better life expectancy, heart failure occurs more and more commonly in the elderly. In the USA approximately 80% of patients discharged from hospital with newly diagnosed heart failure are over 65 years of age, whereas 50% are over 75. The average 5-year mortality rate is about 50% in subjects with systolic dysfunction and similar in those with preserved left ventricular systolic function. Disorders of the cardiovascular system occurring in the elderly (e.g. increased left ventricular mass, myocardial rigidity, atrial fibrillation, decreased maximum oxygen uptake in cardiopulmonary exercise tests) result from the physiological ageing; they may also be caused by a concomitant cardiac failure syndrome. In the elderly, heart failure is often accompanied by concomitant conditions that often make diagnosis and treatment of chronic heart disease difficult. Non-specific clinical symptoms in the elderly as well as those associated with age (e.g. easy fatigability, exertional dyspnea) make a correct diagnosis difficult. The recognized biochemical marker of heart failure--brain natriuretic peptide, N-terminal pro-brain natriuretic peptide--has a limited diagnostic value in the elderly. Echocardiography plays a key role in the diagnosis. Owing to altered metabolism, impairment of hepatic processes to various degrees and decreased renal excretion of drugs, treatment requires attention, individual choice of drugs and doses, as well as periodic modification of both the doses and the intervals between them. Correct treatment improves quality of life and prolongs it. The aim of the present work is to present the differences in the pathophysiology, diagnostic evaluation and management of chronic heart failure in the elderly, in light of the current views and standards.
Pol Arch Med Wewn 2008 Oct
PMID:Chronic heart failure in the elderly: a current medical problem. 1911 19

Transcatheter valve replacement has recently been introduced into clinical practice. We present our first experience with non-surgical, transcatheter pulmonary valve implantation in four patients (age 27-31 years, three females) with repaired congenital heart disease who required reintervention to the right ventricular outflow tract due to dysfunction of valve homograft. The Medtronic Melody Transcatheter Pulmonary Valve was successfully implanted in all four patients without complications, releasing the outflow obstruction, and normal function of the biological valve.
Kardiol Pol 2009 Jan
PMID:[Non-surgical, transcatheter pulmonary valve implantation - first experience]. 1925 2

A case of a 2-day-old newborn with congenital heart disease, pulmonary atresia and ventricular septal defect is described. The Blalock-Taussig shunt was created 6 days after birth. After the procedure, the newborn developed symptoms of increased pulmonary blood flow and respiratory distress. We decided to close one of the major aortopulmonary collateral arteries with the Gianturco coil on the 41st day after birth, however the results were not satisfactory. On the 66th day of infant life (by that time the patient weighted 3 kg), another procedure with the Amplatzer vascular plug was performed. This procedure was successful. After a few days the infant was discharged from hospital.
Kardiol Pol 2009 Apr
PMID:[Closure of major aorto-pulmonary collateral artery with the Amplatzer vascular plug in an infant with pulmonary atresia and ventricular septal defect - a difficult therapeutic problem]. 1949 56

Osteoporosis and osteoporotic bone fractures becomes a serious life threat for women after menopause. Estrogens, mainly through alpha type receptor, act on immunological cells, osteoblasts and osteoclasts, causing increase of bone mineral density and decline of risk of fractures. Conventional hormonal replacement therapy (in peculiarity its estrogens) is effective regimen, applied in prevention and treatment of osteoporosis. Observational studies carried out in past revealed its beneficial influence on cardiovascular disease. However, randomized clinical trials and newer observational studies neglected those conclusions. It was shown that hormonal replacement therapy has adverse effects on: risk of heart disease among older women, thromboemolic disease, stroke and breast cancer among some groups of women. On the other hand, hormonal therapy is effective for menopause symptoms, risk of death and in some clinical cases it might be used in osteoporosis treatment. On base of precise scientific data, particular group of patients may be selected, for which use of hormonal replacement therapy will be especially valuable.
Pol Merkur Lekarski 2009 Jul
PMID:[Conventional hormonal replacement therapy in treatment of osteoporosis]. 1965 Apr 36

A case of a patient treated with antiarrhythmic drugs for ventricular arrhythmia occurring after viral infection of the respiratory tract is presented. In the course of preliminary cardiologic examination no organic heart disease was diagnosed. Due to numerous ventricular extrasystolic beats (16,500 per day) and short runs of non-sustained ventricular tachycardia (maximum of 4 subsequent beats) propafenone was introduced. Persistent arrhythmia was a reason for adding sotalol to that treatment in an outpatient clinic. After three weeks of such treatment the patient presented cardiac arrest in the mechanism of ventricular tachycardia and fibrillation. Successful resuscitation and drug discontinuation led to complete resolution of the life-threatening arrhythmia. No inducible complex ventricular arrhythmia was observed during electrophysiologic examination.
Kardiol Pol 2009 Aug
PMID:[Life-threatening ventricular arrhythmia during simultaneous administration of propafenone and sotatol]. 1978 92

Heart disease and renal failure occurring together, constitute a potential threat to life, especially in the elderly. Diseases of the cardiovascular system are the main factor in morbidity and mortality in patients with chronic kidney disease. On the other hand, chronic kidney disease is considered a risk factor for cardiovascular diseases. Identified major nephrological problems, especially chronic renal disease and acute kidney damage, as the most aggravating cardiac patients. Stressed the importance of clinical, preventive measures and prognosis in contrast nephropathy
Pol Merkur Lekarski 2010 Feb
PMID:[Nephrology complications in cardiology]. 2036 46

Coronary fistula is a rare congenital heart disease. Usually it is diagnosed because of mild clinical event and sometimes detected by coronary angiography performed during acute phase of myocardial infarction. When the coronary fistula have an aneurysmatic form, it should be closed due to the risk of rupture and sudden death, especially when volumetric and pressure overload or coronary steal syndrome are present. The closure may be performed invasively or non-invasively; the latter method is prefered in asymptomatic patients.
Kardiol Pol 2010 Apr
PMID:[A patient with coronaro-pulmonary fistula and acute coronary syndrome - clinical and diagnostic problem]. 2042 8

Growth differentiation factor-15 (GDF-15) is a cytokine with cardioprotective properties, which inhibits hypertrophy, cardiac remodeling and apoptosis. Participates in the life and cell death. The concentration of GDF-15 rapidly increases under the influence of ischemia-reperfusion damage to heart muscle, oxidative stress, inflammatory cytokines and pressure overload. In patients with acute coronary syndromes, heart failure and pulmonary embolism provides independent prognostic information, both short-and long-term. It is potentially a new marker of risk stratification in patients with heart disease and therapeutic decision making.
Pol Merkur Lekarski 2010 Jun
PMID:[Growth differentiation factor 15--a new marker in heart diseases]. 2064 7


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>